Patents Assigned to ENLIVEX THERAPEUTICS LTD.
-
Publication number: 20220280563Abstract: Methods of use for treating osteoarthritis or vanishing bone disease in a subject in need, including methods of direct administration of a composition of early apoptotic cells or an apoptotic supernatant into or adjacent to the affected joint or bone tissue. Methods of use may reduce pain, swelling, inflammation, bone loss, and or cartilage degeneration, and may increase freedom of movement at an affected joint.Type: ApplicationFiled: August 23, 2020Publication date: September 8, 2022Applicant: Enlivex Therapeutics Ltd.Inventors: Dror MEVORACH, Shai NOVIK
-
Publication number: 20220133799Abstract: Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. In certain instances, compositions may include additional agents.Type: ApplicationFiled: January 4, 2022Publication date: May 5, 2022Applicant: Enlivex Therapeutics Ltd.Inventors: Shai Novik, Dror Mevorach
-
Patent number: 11318163Abstract: Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. Further, anti-inflammatory cytokine release may be reduced. In certain instances, compositions may include additional agents.Type: GrantFiled: November 4, 2019Date of Patent: May 3, 2022Assignee: ENLIVEX THERAPEUTICS LTDInventors: Shai Novik, Dror Mevorach
-
Patent number: 11304976Abstract: Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. In certain instances, compositions may include additional agents.Type: GrantFiled: November 19, 2018Date of Patent: April 19, 2022Assignee: ENLIVEX THERAPEUTICS LTDInventors: Shai Novik, Dror Mevorach
-
Publication number: 20210228633Abstract: Compositions disclosed herein, and methods of use thereof included those for inhibiting or reducing the incidence of cytokine release syndrome or cytokine storm in a subject undergoing CAR T-cell therapy, methods of treating a cancer or tumor, methods of reducing tumor load, methods of reducing the size or growth rate of a cancer or a tumor, and methods of extending of the survival of a subject suffering from a cancer or tumor, wherein the subjects are administered compositions comprising apoptotic cells or apoptotic cell supernatants. Compositions and methods of use thereof may increase the efficacy of a CAR T-cell cancer therapy. Disclosed herein are also compositions and methods of use thereof for decreasing or inhibiting cytokine production in a subject experiencing cytokine release syndrome or cytokine storm. In certain instances compositions may include additional chemotherapeutic or immunomodulatory agents.Type: ApplicationFiled: April 5, 2021Publication date: July 29, 2021Applicant: ENLIVEX THERAPEUTICS LTD.Inventors: Shai NOVIK, Dror MEVORACH
-
Patent number: 11000548Abstract: Compositions disclosed herein, and methods of use thereof included those for inhibiting or reducing the incidence of cytokine release syndrome or cytokine storm in a subject undergoing CAR T-cell therapy, methods of treating a cancer or tumor, methods of reducing tumor load, methods of reducing the size or growth rate of a cancer or a tumor, and methods of extending of the survival of a subject suffering from a cancer or tumor, wherein the subjects are administered compositions comprising apoptotic cells or apoptotic cell supernatants. Compositions and methods of use thereof may increase the efficacy of a CAR T-cell cancer therapy. Disclosed herein are also compositions and methods of use thereof for decreasing or inhibiting cytokine production in a subject experiencing cytokine release syndrome or cytokine storm. In certain instances compositions may include additional chemotherapeutic or immunomodulatory agents.Type: GrantFiled: August 24, 2017Date of Patent: May 11, 2021Assignee: ENLIVEX THERAPEUTICS LTDInventors: Shai Novik, Dror Mevorach
-
Publication number: 20210106617Abstract: Compositions disclosed herein, and methods of use thereof included those for inhibiting or reducing the incidence of cytokine release syndrome or cytokine storm in a subject undergoing CAR T-cell therapy, methods of treating a cancer or tumor, methods of reducing tumor load, methods of reducing the size or growth rate of a cancer or a tumor, and methods of extending of the survival of a subject suffering from a cancer or tumor, wherein the subjects are administered compositions comprising apoptotic cells or apoptotic cell supernatants. Compositions and methods of use thereof may increase the efficacy of a CAR T-cell cancer therapy. Disclosed herein are also compositions and methods of use thereof for decreasing or inhibiting cytokine production in a subject experiencing cytokine release syndrome or cytokine storm. In certain instances compositions may include additional chemotherapeutic or immunomodulatory agents.Type: ApplicationFiled: August 24, 2017Publication date: April 15, 2021Applicant: ENLIVEX THERAPEUTICS LTD.Inventors: Shai NOVIK, Dror MEVORACH
-
Patent number: 10927343Abstract: The present application provides pharmaceutical compositions comprising a population of mononuclear-enriched cells in an early-apoptotic state, methods for the production of said compositions and uses thereof in the treatment of diseases characterized by pathological immune responses. The pharmaceutical compositions may be used in treatment of conditions such as, but not limited to, graft versus host disease (GVHD) and autoimmune diseases including but not limited to inflammatory bowel disease, gout and arthritis.Type: GrantFiled: July 29, 2018Date of Patent: February 23, 2021Assignee: ENLIVEX THERAPEUTICS LTDInventors: Dror Mevorach, Inna Reiner
-
Publication number: 20210038644Abstract: Cell preparations comprising a pooled and enriched, mononuclear apoptotic cell population, and a method of preparing this cell preparation are described. The pooled mononuclear apoptotic cell preparation may be obtained from pooled, allogeneic white blood cell fractions that are pooled prior to or following induction of apoptosis. Further, described herein are methods of use of these pooled apoptotic cell preparations for treating an immune disease, an inflammatory disease, an autoimmune disease, or infertility in a subject. For example, a pooled apoptotic cell preparation may be used to treat graft versus host disease (GVHD) in an allogeneic subject.Type: ApplicationFiled: October 21, 2020Publication date: February 11, 2021Applicant: ENLIVEX THERAPEUTICS LTDInventors: Dror MEVORACH, Shai NOVIK
-
Patent number: 10857181Abstract: Cell preparations comprising a pooled and enriched, mononuclear apoptotic cell population, and a method of preparing this cell preparation are described. The pooled mononuclear apoptotic cell preparation may be obtained from pooled, allogeneic white blood cell fractions that are pooled prior to or following induction of apoptosis. Further, described herein are methods of use of these pooled apoptotic cell preparations for treating an immune disease, an inflammatory disease, an autoimmune disease, or infertility in a subject. For example, a pooled apoptotic cell preparation may be used to treat graft versus host disease (GVHD) in an allogeneic subject.Type: GrantFiled: April 21, 2016Date of Patent: December 8, 2020Assignee: ENLIVEX THERAPEUTICS LTDInventors: Dror Mevorach, Shai Novik
-
Publication number: 20200289557Abstract: Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. Further, anti-inflammatory cytokine release may be reduced. In certain instances, compositions may include additional agents.Type: ApplicationFiled: May 28, 2020Publication date: September 17, 2020Applicant: ENLIVEX THERAPEUTICS LTD.Inventors: Shai NOVIK, Dror Mevorach
-
Publication number: 20200121718Abstract: Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. Further, anti-inflammatory cytokine release may be reduced. In certain instances, compositions may include additional agents.Type: ApplicationFiled: November 4, 2019Publication date: April 23, 2020Applicant: ENLIVEX THERAPEUTICS LTD.Inventors: Shai NOVIK, Dror MEVORACH
-
Publication number: 20200061116Abstract: Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. Further, anti-inflammatory cytokine release may be reduced. In certain instances, compositions may include additional agents.Type: ApplicationFiled: October 7, 2019Publication date: February 27, 2020Applicant: ENLIVEX THERAPEUTICS LTD.Inventors: Shai NOVIK, Dror MEVORACH
-
Publication number: 20200009192Abstract: Methods of use of early apoptotic cell populations and compositions thereof disclosed herein, including methods of treating a cancer or a tumor, extending survival times of a subject suffering from a cancer or a tumor, and reducing the size or reducing the growth rate of a cancer or a tumor, wherein subjects are administered apoptotic cells or compositions thereof. Cancers may include solid tumors or diffuse cancers, for example leukemia. In certain instances compositions may include additional chemotherapeutic agent. Further, inactivated early apoptotic cell populations are disclosed and methods of making the same.Type: ApplicationFiled: September 19, 2019Publication date: January 9, 2020Applicant: ENLIVEX THERAPEUTICS LTDInventors: Shai NOVIK, Dror MEVORACH
-
Publication number: 20200009191Abstract: Compositions disclosed herein, and methods of use thereof included those for inhibiting or reducing the incidence of cytokine release syndrome or cytokine storm in a subject undergoing CAR T-cell therapy, methods of treating a cancer or tumor, methods of reducing tumor load, methods of reducing the size or growth rate of a cancer or a tumor, and methods of extending of the survival of a subject suffering from a cancer or tumor, wherein the subjects are administered compositions comprising apoptotic cells or apoptotic cell supernatants. Compositions and methods of use thereof may increase the efficacy of a CAR T-cell cancer therapy. Disclosed herein are also compositions and methods of use thereof for decreasing or inhibiting cytokine production in a subject experiencing cytokine release syndrome or cytokine storm. In certain instances compositions may include additional chemotherapeutic or immunomodulatory agents.Type: ApplicationFiled: September 19, 2019Publication date: January 9, 2020Applicant: ENLIVEX THERAPEUTICS LTDInventors: Shai NOVIK, Dror MEVORACH
-
Publication number: 20190083535Abstract: Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. In certain instances, compositions may include additional agents.Type: ApplicationFiled: November 19, 2018Publication date: March 21, 2019Applicant: ENLIVEX THERAPEUTICS LTD.Inventors: Shai Novik, Dror Mevorach
-
Publication number: 20190024048Abstract: The present application provides pharmaceutical compositions comprising a population of mononuclear-enriched cells in an early-apoptotic state, methods for the production of said compositions and uses thereof in the treatment of diseases characterized by pathological immune responses. The pharmaceutical compositions may be used in treatment of conditions such as, but not limited to, graft versus host disease (GVHD) and autoimmune diseases including but not limited to inflammatory bowel disease, gout and arthritis.Type: ApplicationFiled: July 29, 2018Publication date: January 24, 2019Applicant: ENLIVEX THERAPEUTICS LTDInventors: Dror MEVORACH, Inna Reiner
-
Patent number: 10077426Abstract: The present application provides pharmaceutical compositions comprising a population of mononuclear-enriched cells in an early-apoptotic state, methods for the production of said compositions and uses thereof in the treatment of diseases characterized by pathological immune responses. The pharmaceutical compositions may be used in treatment of conditions such as, but not limited to, graft versus host disease (GVHD) and autoimmune diseases including but not limited to inflammatory bowel disease, gout and arthritis.Type: GrantFiled: December 5, 2013Date of Patent: September 18, 2018Assignee: Enlivex Therapeutics LtdInventors: Dror Mevorach, Inna Reiner
-
Publication number: 20180104277Abstract: Cell preparations comprising a pooled and enriched, mononuclear apoptotic cell population, and a method of preparing this cell preparation are described. The pooled mononuclear apoptotic cell preparation may be obtained from pooled, allogeneic white blood cell fractions that are pooled prior to or following induction of apoptosis. Further, described herein are methods of use of these pooled apoptotic cell preparations for treating an immune disease, an inflammatory disease, an autoimmune disease, or infertility in a subject. For example, a pooled apoptotic cell preparation may be used to treat graft versus host disease (GVHD) in an allogeneic subject.Type: ApplicationFiled: April 21, 2016Publication date: April 19, 2018Applicant: ENLIVEX THERAPEUTICS LTD.Inventors: Dror MEVORACH, Shai NOVIK
-
Publication number: 20180094244Abstract: Compositions disclosed herein, and methods of use thereof included those for inhibiting or reducing the incidence of cytokine release syndrome or cytokine storm in a subject undergoing CAR T-cell therapy, wherein the subjects are administered compositions including apoptotic cells or apoptotic cell supernatants. In certain instances compositions and methods of use thereof disclosed herein do not reduce the efficacy of the CAR T-cell cancer therapy. Disclosed herein are also compositions and methods of use thereof for decreasing or inhibiting cytokine production in a subject experiencing cytokine release syndrome or cytokine storm including administration of a composition including apoptotic cells or an apoptotic cell supernatant.Type: ApplicationFiled: February 18, 2016Publication date: April 5, 2018Applicant: Enlivex Therapeutics Ltd.Inventors: Shai NOVIK, Dror MEVORACH